164 related articles for article (PubMed ID: 30706585)
41. Comparison and functional characterisation of peripheral blood mononuclear cells isolated from filarial lymphoedema and endemic normals of a South Indian population.
Nathan AA; Dixit M; Babu S; Balakrishnan AS
Trop Med Int Health; 2017 Nov; 22(11):1414-1427. PubMed ID: 28869696
[TBL] [Abstract][Full Text] [Related]
42. Knowledge and perceptions about lymphatic filariasis: a study during the programme to eliminate lymphatic filariasis in an urban community of Orissa, India.
Rath K; Nath N; Shaloumy M; Swain BK; Suchismita M; Babu BV
Trop Biomed; 2006 Dec; 23(2):156-62. PubMed ID: 17322817
[TBL] [Abstract][Full Text] [Related]
43. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis.
Debrah AY; Mand S; Specht S; Marfo-Debrekyei Y; Batsa L; Pfarr K; Larbi J; Lawson B; Taylor M; Adjei O; Hoerauf A
PLoS Pathog; 2006 Sep; 2(9):e92. PubMed ID: 17044733
[TBL] [Abstract][Full Text] [Related]
44. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
[TBL] [Abstract][Full Text] [Related]
45. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis.
Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG
Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882
[TBL] [Abstract][Full Text] [Related]
46. Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.
Richards FO; Eigege A; Miri ES; Kal A; Umaru J; Pam D; Rakers LJ; Sambo Y; Danboyi J; Ibrahim B; Adelamo SE; Ogah G; Goshit D; Oyenekan OK; Mathieu E; Withers PC; Saka YA; Jiya J; Hopkins DR
PLoS Negl Trop Dis; 2011 Oct; 5(10):e1346. PubMed ID: 22022627
[TBL] [Abstract][Full Text] [Related]
47. A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.
Ramaiah KD; Vijay Kumar KN; Hosein E; Krishnamoorthy P; Augustin DJ; Snehalatha KS; Nanda B; Das PK
Ann Trop Med Parasitol; 2006 Jun; 100(4):345-61. PubMed ID: 16762115
[TBL] [Abstract][Full Text] [Related]
48. Lymphatic filariasis: patients and the global elimination programme.
Mackenzie CD; Lazarus WM; Mwakitalu ME; Mwingira U; Malecela MN
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S41-51. PubMed ID: 19843397
[TBL] [Abstract][Full Text] [Related]
49. Mass drug administration under the programme to eliminate lymphatic filariasis in Orissa, India: a mixed-methods study to identify factors associated with compliance and non-compliance.
Babu BV; Mishra S
Trans R Soc Trop Med Hyg; 2008 Dec; 102(12):1207-13. PubMed ID: 18632125
[TBL] [Abstract][Full Text] [Related]
50. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
Hooper PJ; Bradley MH; Biswas G; Ottesen EA
Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
[TBL] [Abstract][Full Text] [Related]
51. Modelling lymphatic filariasis elimination in American Samoa: GEOFIL predicts need for new targets and six rounds of mass drug administration.
McLure A; Graves PM; Lau C; Shaw C; Glass K
Epidemics; 2022 Sep; 40():100591. PubMed ID: 35816826
[TBL] [Abstract][Full Text] [Related]
52. Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.
Tavul L; Laman M; Howard C; Kotty B; Samuel A; Bjerum C; O'Brian K; Kumai S; Amuga M; Lorry L; Kerry Z; Kualawi M; Karl S; Makita L; John LN; Bieb S; Wangi J; Weil GJ; Goss CW; Tisch DJ; Pomat W; King CL; Robinson LJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010096. PubMed ID: 35139070
[TBL] [Abstract][Full Text] [Related]
53. A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti.
Boyd A; Won KY; McClintock SK; Donovan CV; Laney SJ; Williams SA; Pilotte N; Streit TG; Beau de Rochars MV; Lammie PJ
PLoS Negl Trop Dis; 2010 Mar; 4(3):e640. PubMed ID: 20351776
[TBL] [Abstract][Full Text] [Related]
54. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
[TBL] [Abstract][Full Text] [Related]
55. Mass treatment to eliminate filariasis in Papua New Guinea.
Bockarie MJ; Tisch DJ; Kastens W; Alexander ND; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
N Engl J Med; 2002 Dec; 347(23):1841-8. PubMed ID: 12466508
[TBL] [Abstract][Full Text] [Related]
56. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of lymphatic filariasis in a tea garden worker population of Dibrugarh (Assam), India after six rounds of mass drug administration.
Khan AM; Dutta P; Sarmah CK; Baruah NK; Das S; Pathak AK; Sarmah P; Hussain ME; Mahanta J
J Vector Borne Dis; 2015 Dec; 52(4):314-20. PubMed ID: 26714512
[TBL] [Abstract][Full Text] [Related]
58. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
[TBL] [Abstract][Full Text] [Related]
59. Awareness and coverage of mass drug administration for elimination of lymphatic filariasis: a community based cross sectional study in Nepal.
Adhikari RK; Sherchand JB; Mishra SR; Ranabhat K; Wagle RR
J Community Health; 2015 Feb; 40(1):34-40. PubMed ID: 24996654
[TBL] [Abstract][Full Text] [Related]
60. Adverse reactions following mass drug administration during the Programme to Eliminate Lymphatic Filariasis in Orissa State, India.
Babu BV; Rath K; Kerketta AS; Swain BK; Mishra S; Kar SK
Trans R Soc Trop Med Hyg; 2006 May; 100(5):464-9. PubMed ID: 16288792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
